NASDAQ$IFRX
InflaRx NV · Q2 2026 earnings
Q2 2026 earnings · · Before market open · Investor relations
Briefing
InflaRx NV reported Q2 2026 financial results with minimal revenue and a net loss of €10.6 million.
InflaRx NV (IFRX) released its Q2 2026 results on August 6, 2026, showing revenues of €39,432 and a net loss of €10.65 million (€0.09 per share). The company highlighted progress in izicopan development for AAV and renal diseases, along with a strengthened balance sheet following a $150 million offering, with total available funds of €158.4 million expected to fund operations through 2029.
- Q2 2026 revenues totaled €39,432 with operating loss of €7.05 million.
- Net loss for the quarter was €10.65 million or €0.09 per share.
- Cash, cash equivalents and marketable securities reached €158.4 million as of June 30, 2026.
- Focus on izicopan advancement in ANCA-associated vasculitis and other indications; Capital Markets Day planned for October 2026.
Headline financials
Revenue & EPS history
InflaRx · Revenue · Quarterly
€45.5K
Forward guidance
Cash runway extended through 2029 following recent financing; clinical preparations for izicopan ongoing with PK bridging study in China expected late 2026 and proof-of-concept data targeted for 2027.
Tailwinds
- Strengthened balance sheet with €158.4 million in funds
- Progress on izicopan development strategy in AAV and renal diseases
- Virtual Capital Markets Day scheduled for October 8, 2026
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports
+0.3%
Avg return
Earnings day
+5.7%
Avg return
5 days after
+7.4%
Avg return
30 days after
43%
6 / 14 earnings
Positive
+21.9%
Q4 2019
Best reaction
-17.2%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q3 2026 | -6.8% | -14.8% | -25.9% | |
| Q2 2024 | -2.1% | -2.1% | +7.8% | |
| Q3 2023 | -17.2% | -18.9% | -20.1% | |
| Q2 2023 | +3.6% | -5.5% | +6.0% | |
| Q1 2023 | +11.8% | +7.2% | -8.8% | |
| Q3 2022 | -5.9% | +97.1% | +59.7% | |
| Q1 2022 | +6.6% | +8.0% | +2.2% | |
| Q4 2020 | +2.8% | -4.1% | -5.1% | |
| Q3 2020 | -0.5% | +5.7% | +3.6% | |
| Q1 2020 | +3.4% | +2.4% | -33.8% | |
| Q4 2019 | +21.9% | +17.6% | +52.1% | |
| Q2 2019 | -3.8% | -0.8% | +13.5% | |
| Q4 2018 | -4.9% | -6.5% | +25.6% | |
| Q4 2017 | -5.1% | -5.3% | +26.9% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro